Arvinas, Novartis in ARV-766 Prostate Cancer License Pact
By Colin Kellaher
Clinical-stage biotechnology company Arvinas has struck a licensing and asset-sale agreement potentially worth more than $1 billion with Swiss drugmaker Novartis.
Arvinas on Thursday said Novartis will make an upfront payment of $150 million in exchange for an exclusive license for the development and commercialization of ARV-766, the New Haven, Conn., company's second-generation Protac androgen receptor degrader for patients with prostate cancer, as well as the acquisition of its preclinical AR-V7 program.
Arvinas said it is also eligible to receive up to $1.01 billion in development, regulatory and commercial milestone payments, along with royalties on sales for ARV-766.
Arvinas said Novartis will be responsible for worldwide clinical development and commercialization of ARV-766, adding that it expects the partnership to accelerate and broaden the drug's development as a potential first-in-class treatment option for patients with prostate cancer.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 11, 2024 07:42 ET (11:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
3 Cheap and Dependable Dividend-Growth Stocks to Buy
-
The Best Bank Stocks to Buy
-
After Earnings, Is Roblox Stock a Buy, Sell, or Fairly Valued?
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?